ImmunoGen Inc. (NASDAQ:IMGN) fell 1.4% during trading on Wednesday . The company traded as low as $2.79 and last traded at $2.84, with a volume of 564,747 shares. The stock had previously closed at $2.88.

A number of research firms recently commented on IMGN. Zacks Investment Research raised shares of ImmunoGen from a “sell” rating to a “hold” rating in a report on Tuesday, August 9th. Jefferies Group reaffirmed a “buy” rating and issued a $6.00 price target (down previously from $13.00) on shares of ImmunoGen in a report on Friday, August 5th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of ImmunoGen in a report on Wednesday, June 8th. JPMorgan Chase & Co. set a $5.00 price target on shares of ImmunoGen and gave the stock a “hold” rating in a report on Friday, August 5th. Finally, Cowen and Company reaffirmed a “hold” rating on shares of ImmunoGen in a report on Monday, June 6th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. ImmunoGen presently has a consensus rating of “Hold” and an average price target of $11.72.

The company’s 50-day moving average price is $2.92 and its 200-day moving average price is $5.12. The stock’s market capitalization is $251.50 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/immunogen-inc-imgn-trading-down-1-4.html

ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.12. ImmunoGen had a negative net margin of 239.42% and a negative return on equity of 530.98%. The firm had revenue of $7.41 million for the quarter, compared to analysts’ expectations of $17.11 million. During the same quarter in the previous year, the company earned ($0.35) EPS. The company’s quarterly revenue was down 41.2% compared to the same quarter last year. Equities research analysts anticipate that ImmunoGen Inc. will post ($1.61) earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of IMGN. Norges Bank bought a new stake in shares of ImmunoGen during the fourth quarter valued at about $20,773,000. Fisher Asset Management LLC bought a new stake in shares of ImmunoGen during the first quarter valued at about $2,244,000. Ngam Advisors L.P. boosted its stake in shares of ImmunoGen by 21.6% in the first quarter. Ngam Advisors L.P. now owns 188,207 shares of the biotechnology company’s stock valued at $1,604,000 after buying an additional 33,377 shares in the last quarter. Wrapmanager Inc. boosted its stake in shares of ImmunoGen by 9.4% in the first quarter. Wrapmanager Inc. now owns 15,877 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 1,368 shares in the last quarter. Finally, BlackRock Group LTD boosted its stake in shares of ImmunoGen by 10.9% in the first quarter. BlackRock Group LTD now owns 96,428 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 9,496 shares in the last quarter. Institutional investors own 91.63% of the company’s stock.

About ImmunoGen

ImmunoGen, Inc (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Company’s clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells.

5 Day Chart for NASDAQ:IMGN

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.